Form D · Pharmaceuticals

LYZER DIAGNOSTICS INC

Boulder, CO · CIK 0001337540

Offering snapshot reported Sep 15, 2009 · SEC filing

Reported sold: $1.34M
Investors reported: 40
Minimum accepted: $0
First sale: Jan 5, 2008

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Sep 15, 2009	Amendment	$1,338,000	No comparison	40	SEC filing
Oct 27, 2008	Paper	Not reported	No comparison	Not reported	SEC filing
Aug 26, 2005	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Not reported
Exemptions: 06
Duration over one year: Yes
Business combination: No

Sales commissions: $134K (estimated)
Finders' fees: $0
Form D file number: 021-80612

Original Form D filed October 27, 2008 indicated an offering of $495,000. Offering was extended until August 31, 2009 and increased in size prior to date it was terminated.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Aaron Capital Incorporated	28538

Source: Form D, filed Sep 15, 2009. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Paul Dragul	Director
Steven P. Tyrrell	Director, Executive
Barry Vant Hull	Director, Executive
Donald Walford	Director
David S. Wolfe	Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

6655 Lookout Road Suite 120
Boulder, CO, 80301